238 related articles for article (PubMed ID: 22196450)
1. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma.
Schaeffeler E; Hellerbrand C; Nies AT; Winter S; Kruck S; Hofmann U; van der Kuip H; Zanger UM; Koepsell H; Schwab M
Genome Med; 2011 Dec; 3(12):82. PubMed ID: 22196450
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance.
Heise M; Lautem A; Knapstein J; Schattenberg JM; Hoppe-Lotichius M; Foltys D; Weiler N; Zimmermann A; Schad A; Gründemann D; Otto G; Galle PR; Schuchmann M; Zimmermann T
BMC Cancer; 2012 Mar; 12():109. PubMed ID: 22439694
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma.
Lautem A; Heise M; Gräsel A; Hoppe-Lotichius M; Weiler N; Foltys D; Knapstein J; Schattenberg JM; Schad A; Zimmermann A; Otto G; Lang H; Galle PR; Schuchmann M; Zimmermann T
Int J Oncol; 2013 Apr; 42(4):1297-304. PubMed ID: 23440379
[TBL] [Abstract][Full Text] [Related]
4. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
Nies AT; Koepsell H; Winter S; Burk O; Klein K; Kerb R; Zanger UM; Keppler D; Schwab M; Schaeffeler E
Hepatology; 2009 Oct; 50(4):1227-40. PubMed ID: 19591196
[TBL] [Abstract][Full Text] [Related]
5. Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.
Minematsu T; Iwai M; Umehara K; Usui T; Kamimura H
Drug Metab Dispos; 2010 Jan; 38(1):1-4. PubMed ID: 19833842
[TBL] [Abstract][Full Text] [Related]
6. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.
Al-Abdulla R; Lozano E; Macias RIR; Monte MJ; Briz O; O'Rourke CJ; Serrano MA; Banales JM; Avila MA; Martinez-Chantar ML; Geier A; Andersen JB; Marin JJG
Br J Pharmacol; 2019 Mar; 176(6):787-800. PubMed ID: 30592786
[TBL] [Abstract][Full Text] [Related]
8. [Low expression of SLC22A1 is associated with a poor prognosis of hepatocellular carcinoma: analysis of 303 patients].
Wang ST; Shen SL; Hua YP; Chen B; Kuang M; Li SQ; He Q; Peng BG
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Oct; 35(10):1417-21. PubMed ID: 26547334
[TBL] [Abstract][Full Text] [Related]
9. Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFβ.
Vollmar J; Kim YO; Marquardt JU; Becker D; Galle PR; Schuppan D; Zimmermann T
Am J Physiol Gastrointest Liver Physiol; 2019 Aug; 317(2):G195-G202. PubMed ID: 31241979
[TBL] [Abstract][Full Text] [Related]
10. Relationship between changes in the exon-recognition machinery and SLC22A1 alternative splicing in hepatocellular carcinoma.
Soto M; Reviejo M; Al-Abdulla R; Romero MR; Macias RIR; Boix L; Bruix J; Serrano MA; Marin JJG
Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165687. PubMed ID: 31953214
[TBL] [Abstract][Full Text] [Related]
11. Functional inhibition of Oct leads to HNF4α upregulation.
Vollmar J; Kim YO; Marquardt JU; Galle PR; Schuppan D; Zimmermann T
Exp Ther Med; 2021 Apr; 21(4):349. PubMed ID: 33732322
[TBL] [Abstract][Full Text] [Related]
12. Diabetes medication associates with DNA methylation of metformin transporter genes in the human liver.
García-Calzón S; Perfilyev A; Männistö V; de Mello VD; Nilsson E; Pihlajamäki J; Ling C
Clin Epigenetics; 2017; 9():102. PubMed ID: 28947922
[TBL] [Abstract][Full Text] [Related]
13. Impact of Organic Cation Transporters (OCT-SLC22A) on Differential Diagnosis of Intrahepatic Lesions.
Visentin M; van Rosmalen BV; Hiller C; Bieze M; Hofstetter L; Verheij J; Kullak-Ublick GA; Koepsell H; Phoa SS; Tamai I; Bennink RJ; van Gulik TM; Stieger B
Drug Metab Dispos; 2017 Feb; 45(2):166-173. PubMed ID: 27903597
[TBL] [Abstract][Full Text] [Related]
14. Genomic imprinting of the IGF2R/AIR locus is conserved between bovines and mice.
Liu X; Huo H; Jin L; Dong Y; Li D; Zhang C; Li S
Theriogenology; 2022 Mar; 180():121-129. PubMed ID: 34971973
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinical significance of organic cation transporter family in glioblastoma multiforme.
Lian Q; Xiao S; Wang Y; Wang H; Xie D
Ir J Med Sci; 2022 Jun; 191(3):1115-1121. PubMed ID: 34080124
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1.
Chen M; Neul C; Schaeffeler E; Frisch F; Winter S; Schwab M; Koepsell H; Hu S; Laufer S; Baker SD; Sparreboom A; Nies AT
Clin Pharmacol Ther; 2020 Jan; 107(1):227-237. PubMed ID: 31350763
[TBL] [Abstract][Full Text] [Related]
17. Genetic and Epigenetic Regulation of Organic Cation Transporters.
Kölz C; Schaeffeler E; Schwab M; Nies AT
Handb Exp Pharmacol; 2021; 266():81-100. PubMed ID: 33674913
[TBL] [Abstract][Full Text] [Related]
18. Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3.
Sala-Rabanal M; Li DC; Dake GR; Kurata HT; Inyushin M; Skatchkov SN; Nichols CG
Mol Pharm; 2013 Apr; 10(4):1450-8. PubMed ID: 23458604
[TBL] [Abstract][Full Text] [Related]
19. Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.
Neul C; Hofmann U; Schaeffeler E; Winter S; Klein K; Giacomini KM; Eichelbaum M; Schwab M; Nies AT
Br J Pharmacol; 2021 Mar; 178(6):1459-1474. PubMed ID: 33434947
[TBL] [Abstract][Full Text] [Related]
20. Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis.
Vollmar J; Lautem A; Closs E; Schuppan D; Kim YO; Grimm D; Marquardt JU; Fuchs P; Straub BK; Schad A; Gründemann D; Schattenberg JM; Gehrke N; Wörns MA; Baumgart J; Galle PR; Zimmermann T
Oncotarget; 2017 Dec; 8(70):115667-115680. PubMed ID: 29383190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
